Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment

Stock Information for Adamas Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adamas Pharmaceuticals Inc.

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBI
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, ADMS, and ACBI Shareholders About Its Ongoing Investigations
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ROG, RRD, XLRN, ADMS; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds OMP, ADMS, ACBI and ECHO Shareholders About Its Ongoing Investigations
ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.